Trending...
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- GT Molecular launches two highly sensitive tests for the dangerous UK Variant of SARS-CoV-2 (B.1.1.7)
- Spivey Hall Children's Choir Looks To 2021 Through The Lens of Langston Hughes Poetry
MUNICH - ColoradoDesk -- Garching - OncoBeta® GmbH and their subsidiary OncoBeta Therapeutics Pty Ltd. Australia a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanoma Skin Cancers (NMSCs), announced today that the Rhenium-SCT (Rhenium-188 paste) has been registered on the Australian Register of Therapeutic Goods (ARTG), which is the formal requirement for supply and marketing of the medical device. This advanced radionuclide therapy technology offers a non-invasive, single session, painless treatment with little to no scarring for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs).
The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia having one of the highest incidence rates in the world. According to the Australian Institute of Health and Welfare (AIHW) Non-melanoma skin cancer (NMSC) is the most common cancer diagnosed in Australia, with over 400,000 new cases per year.
"The approval of the Rhenium-SCT in Australia is a great step forward for patients wanting a new non-invasive and painless treatment option for Non-Melanoma Skin cancer." said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH, "We are committed to bringing back quality of life to skin cancer sufferers."
More on Colorado Desk
Nicholas H. Vetter, Chief Operating Officer of OncoBeta said: "after receiving the TGA approval we will now set up local production to make the Rhenium-SCT even more accessible to clinics, physicians and their patients throughout Australia."
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
More on Colorado Desk
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia having one of the highest incidence rates in the world. According to the Australian Institute of Health and Welfare (AIHW) Non-melanoma skin cancer (NMSC) is the most common cancer diagnosed in Australia, with over 400,000 new cases per year.
"The approval of the Rhenium-SCT in Australia is a great step forward for patients wanting a new non-invasive and painless treatment option for Non-Melanoma Skin cancer." said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH, "We are committed to bringing back quality of life to skin cancer sufferers."
More on Colorado Desk
- Qurate Retail Announces Semi-Annual Interest Payment and Excess Regular Cash Dividend Amount Distribution on 3.5% Senior Exchangeable Debentures Due 2031
- Colorado Springs: Mayor Suthers Selects New Fire Chief
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- AlloSource's ProChondrix CR, Cryopreserved Osteochondral Allograft, To Be Featured At The British Patellofemoral Society Meeting
- Dollyhood Records Signs Distribution Deal With Sony!
Nicholas H. Vetter, Chief Operating Officer of OncoBeta said: "after receiving the TGA approval we will now set up local production to make the Rhenium-SCT even more accessible to clinics, physicians and their patients throughout Australia."
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
More on Colorado Desk
- West Coast Recording Artist, Composer and Actor, Blue Ragg$ Releases New Music & Theatrical Video
- Swaggerty's Receives Highest Possible Grade from BRC Food Safety Auditors for 8th Consecutive Year
- Be an Example, Get the Covid Shot
- Fathom Celebrates Black History Month With First Film Series This February
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contact
OncoBeta GmbH - Marketing/Public Relations
Schleißheimer Str. 91
85748 Garching n. Munich GERMANY
info@oncobeta.com
+49 (89) 32667330
OncoBeta GmbH - Marketing/Public Relations
Schleißheimer Str. 91
85748 Garching n. Munich GERMANY
info@oncobeta.com
+49 (89) 32667330
Source: OncoBeta GmbH, 85748 Garching Germany
0 Comments
Latest on Colorado Desk
- DocBuddy Selected as Allscripts App of the Month Centralizes access to medical records on the go
- AI.Reverie Awarded $950 Million IDIQ Contract for U.S. Air Force Advanced Battle Management System (ABMS)
- Updated ASI Book Helps Association Executives Improve Organizational Performance Now and Post-COVID
- BellRock Brands Confirms Previous 2020 Financial Guidance of Merged Companies; Issues 2021 Guidance
- MBK Senior Living Ranks 7th On Fortune Best Workplaces For Aging Services List
- Colorado Springs: Behind the Springs Podcast: COS@150
- droneselite.com Your Team of Trusted RC Drone Professionals
- Hemp extraction company Zelios Colorado is now Gemini Extraction & Refinement Solutions
- Fifth Gen Media announces Darlene Pope as Chairman of the Advisory Council
- MGL Partners Selects Rainbow Housing as Service Provider for Colorado Affordable Housing Community
- Phinge To Launch Netverse, a Rewards-Based Alternative to Apple and Google Using Innovative Proprietary Technology and Patented Mobile Devices
- GT Molecular launches two highly sensitive tests for the dangerous UK Variant of SARS-CoV-2 (B.1.1.7)
- Spivey Hall Children's Choir Looks To 2021 Through The Lens of Langston Hughes Poetry
- MedAware Systems launches Comprehensive Structural Heart Device Surveillance for Reported Events
- ADDING and REPLACING Neat Capital Secures $22.5 Million In Series B Funding Round
- Wohler releases AoIP & Analog options for their iVAM1-1
- Lalit Jalan, visionary business leader, joins as 3Lines India Chairman
- Guidehouse Insights Report Shows Annual Revenue for Utility Customer Experience and Management Technologies Analytics Is Expected to Near $700 Million by 2029
- While Supplies Last: Thermal Transfer Label Sale
- The Business Consultant behind The First Black-owned BP